JP2024538128A - Ｅｈｍｔ１及びｅｈｍｔ２の新規調節因子及びその治療用途 - Google Patents
Ｅｈｍｔ１及びｅｈｍｔ２の新規調節因子及びその治療用途 Download PDFInfo
- Publication number
- JP2024538128A JP2024538128A JP2024522501A JP2024522501A JP2024538128A JP 2024538128 A JP2024538128 A JP 2024538128A JP 2024522501 A JP2024522501 A JP 2024522501A JP 2024522501 A JP2024522501 A JP 2024522501A JP 2024538128 A JP2024538128 A JP 2024538128A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- cycloalkyl
- heteroalkyl
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163256057P | 2021-10-15 | 2021-10-15 | |
| US63/256,057 | 2021-10-15 | ||
| US202263390438P | 2022-07-19 | 2022-07-19 | |
| US63/390,438 | 2022-07-19 | ||
| PCT/US2022/046761 WO2023064586A1 (en) | 2021-10-15 | 2022-10-14 | Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024538128A true JP2024538128A (ja) | 2024-10-18 |
| JP2024538128A5 JP2024538128A5 (https=) | 2025-10-21 |
Family
ID=84357982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024522501A Pending JP2024538128A (ja) | 2021-10-15 | 2022-10-14 | Ｅｈｍｔ１及びｅｈｍｔ２の新規調節因子及びその治療用途 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240368139A1 (https=) |
| EP (1) | EP4416143A1 (https=) |
| JP (1) | JP2024538128A (https=) |
| KR (1) | KR20240148310A (https=) |
| AU (1) | AU2022366869A1 (https=) |
| CA (1) | CA3234693A1 (https=) |
| IL (1) | IL311999A (https=) |
| MX (1) | MX2024004416A (https=) |
| WO (1) | WO2023064586A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116602242B (zh) * | 2023-05-08 | 2024-01-23 | 中国水产科学研究院珠江水产研究所 | 一种提高反季鱼苗成活率的方法 |
| WO2025155882A1 (en) * | 2024-01-19 | 2025-07-24 | Icahn School Of Medicine At Mount Sinai | G9a/glp degradation / disruption compounds and methods of use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3270960A (en) | 1964-09-11 | 1966-09-06 | Sperry Rand Corp | Fluid sensor |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| PL3442947T3 (pl) * | 2016-04-15 | 2023-10-02 | Epizyme, Inc. | Związki arylowe lub heteroarylowe podstawione aminą jako inhibitory ehmt1 i ehmt2 |
| US20200039998A1 (en) * | 2016-12-19 | 2020-02-06 | Epizyme, Inc. | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof |
| US20200113901A1 (en) * | 2017-03-31 | 2020-04-16 | Epizyme, Inc. | Methods of using ehmt2 inhibitors |
| CN110621316B (zh) * | 2017-04-21 | 2024-01-26 | Epizyme股份有限公司 | 用ehmt2抑制剂进行的组合疗法 |
| JP2021500326A (ja) * | 2017-10-18 | 2021-01-07 | エピザイム，インコーポレイティド | 血液障害の予防又は処置にｅｈｍｔ２阻害剤を使用する方法 |
| AU2018353139A1 (en) * | 2017-10-18 | 2020-06-04 | Epizyme, Inc. | Methods of using EHMT2 inhibitors in immunotherapies |
-
2022
- 2022-10-14 JP JP2024522501A patent/JP2024538128A/ja active Pending
- 2022-10-14 KR KR1020247016027A patent/KR20240148310A/ko active Pending
- 2022-10-14 MX MX2024004416A patent/MX2024004416A/es unknown
- 2022-10-14 US US18/701,092 patent/US20240368139A1/en active Pending
- 2022-10-14 AU AU2022366869A patent/AU2022366869A1/en active Pending
- 2022-10-14 IL IL311999A patent/IL311999A/en unknown
- 2022-10-14 CA CA3234693A patent/CA3234693A1/en active Pending
- 2022-10-14 WO PCT/US2022/046761 patent/WO2023064586A1/en not_active Ceased
- 2022-10-14 EP EP22802794.2A patent/EP4416143A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022366869A1 (en) | 2024-05-02 |
| KR20240148310A (ko) | 2024-10-11 |
| US20240368139A1 (en) | 2024-11-07 |
| MX2024004416A (es) | 2024-07-09 |
| EP4416143A1 (en) | 2024-08-21 |
| IL311999A (en) | 2024-06-01 |
| WO2023064586A1 (en) | 2023-04-20 |
| CA3234693A1 (en) | 2023-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3788040B1 (en) | Pyridazinones as parp7 inhibitors | |
| EP3601297B1 (en) | Compounds that inhibit mcl-1 protein | |
| US20230265116A1 (en) | Degradation of (egfr) by conjugation of egfr inhibitors with e3 ligase ligand and methods of use | |
| AU2015232543B2 (en) | 1,3-benzodioxole derivative | |
| KR20250088505A (ko) | 피리미딘-융합 고리 화합물, 및 이의 제조 방법 및 이의 용도 | |
| JP2017178968A (ja) | 化合物、その医薬組成物、及び癌治療用のｉｄｈ１突然変異阻害薬としてのその使用 | |
| JP6522646B2 (ja) | ＲＯＳ１阻害剤としての置換４，５，６，７−テトラヒドロ−ピラゾロ［１，５−α］ピラジン誘導体および５，６，７，８−テトラヒドロ−４Ｈ−ピラゾロ［１，５−α］［１，４］ジアゼピン誘導体 | |
| EP3442947A1 (en) | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors | |
| EA031223B1 (ru) | Соединения, которые ингибируют белок mcl-1 | |
| KR20190017030A (ko) | Dnmt1의 억제제로서의 치환된 피리딘 | |
| EP4055013B1 (en) | Wdr5 inhibitors and modulators | |
| JP2017508779A5 (https=) | ||
| EP3781550A1 (en) | Bicyclic carboxamides and methods of use thereof | |
| JP2024538128A (ja) | Ｅｈｍｔ１及びｅｈｍｔ２の新規調節因子及びその治療用途 | |
| UA129879C2 (uk) | Макроциклічні інгібітори rip2-кінази | |
| WO2023069731A1 (en) | Compounds that mediate protein degradation and methods of use thereof | |
| CN118647610A (zh) | Ehmt1和ehmt2的新型调节剂及其治疗用途 | |
| WO2026055780A1 (en) | Compounds and compositions for treating mc4r related conditions | |
| WO2026093360A1 (en) | Tricyclic compounds for the treatment of cancer | |
| WO2024216164A1 (en) | N2-((5-hydroxy)-2-pyridyl)-pyridine-2,4-diamine derivatives as ehmt1/2 modulators for the treatment of cancer | |
| HK40048232A (en) | Pyridazinones as parp7 inhibitors | |
| HK40048232B (en) | Pyridazinones as parp7 inhibitors | |
| HK40031697A (en) | Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors | |
| HK40031697B (en) | Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251010 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251010 |